1.
|
The CERN-MEDICIS Isotope Separator Beamline
/ CERN-MEDICIS Collaboration
CERN-MEDICIS is an off-line isotope separator facility for the extraction of radioisotopes from irradiated targets of interest to medical applications. The beamline, between the ion source and the collection chamber, consists of ion extraction and focusing elements, and a dipole magnet mass spectrometer recovered from the LISOL facility in Louvain-la-Neuve. [...]
2021 - 8 p.
- Published in : Frontiers in Medicine 8 (2021) 689281
Fulltext: PDF;
|
|
2.
|
CERN-MEDICIS: A Review Since Commissioning in 2017
/ MEDICIS Collaboration
The CERN-MEDICIS (MEDical Isotopes Collected from ISolde) facility has delivered its first radioactive ion beam at CERN (Switzerland) in December 2017 to support the research and development in nuclear medicine using non-conventional radionuclides. Since then, fourteen institutes, including CERN, have joined the collaboration to drive the scientific program of this unique installation and evaluate the needs of the community to improve the research in imaging, diagnostics, radiation therapy and personalized medicine. [...]
2021 - 11 p.
- Published in : Frontiers in Medicine 8 (2021) 693682
Fulltext: PDF;
|
|
3.
|
|
4.
|
First laser ions at the CERN-MEDICIS facility
/ MEDICIS Collaboration
The CERN-MEDICIS facility aims to produce emerging medical radionuclides for the theranostics approach in nuclear medicine with mass separation of ion beams. To enhance the radioisotope yield and purity of collected samples, the resonance ionization laser ion source MELISSA was constructed, and provided the first laser ions at the facility in 2019. [...]
2020 - 9 p.
- Published in : Hyperfine Interact. 241 (2020) 55
Fulltext: PDF;
|
|
5.
|
CERN-MEDICIS: A Unique Facility for the Production of Non-Conventional Radionuclides for the Medical Research
/ Duchemin, Charlotte (CERN) ; Barbero-Soto, Esther (CERN) ; Bernardes, Ana (CERN) ; Catherall, Richard (CERN) ; Chevallay, Eric (CERN) ; Cocolios, Thomas (Leuven U.) ; Dorsival, Alexandre (CERN) ; Fedosseev, Valentin (CERN) ; Fernier, Pascal (CERN) ; Gilardoni, Simone (CERN) et al.
The MEDICIS facility is a unique facility located at CERN dedicated to the production of non-conventional radionuclides for research and development in imaging, diagnostics and radiation therapy. It exploits in a Class A work sector, a dedicated isotope separator beam line, a target irradiation station at the 1.4 GeV Proton Synchroton Booster (PSB) and receives activated targets from external institutes during CERN Long Shut-Downs. [...]
CERN-ACC-2021-010.-
2021 - 5 p.
- Published in : JACoW IPAC 2020 (2020) THVIR13
Fulltext: PDF;
In : 11th International Particle Accelerator Conference, Caen, France, 10 - 15 May 2020, pp.THVIR13
|
|
6.
|
CERN-MEDICIS: Operational indicators to support the production of new medical radionuclides by mass-separation
/ Stora, T (CERN) ; Duchemin, C (CERN) ; Andreazza, W (CERN) ; Aubert, E (CERN) ; Bernerd, C (CERN ; Leuven U.) ; Cocolios, T (Leuven U.) ; Deschamps, M (CERN) ; Dorsival, A (CERN) ; Duraffourg, M (CERN) ; Fedosseev, V (CERN) et al.
CERN-MEDICIS is an isotope mass separation facility for biomedical R&D; located in a class A laboratory, receiving up to 50% of the 1.4GeV PSB protons. It was commissioned with radioactive ion beams in 2017. [...]
2023 - 6 p.
- Published in : J. Phys. : Conf. Ser.: 2687 (2024) , no. 8, pp. 082039
- Published in : JACoW IPAC: 2023 (2023) , pp. WEPM125
Fulltext: PublicationJACoW - PDF; PublicationIOP - PDF;
In : 14th International Particle Accelerator Conference (IPAC 2023), Venice, Italy, 7 - 12 May 2023, pp.082039
|
|
7.
|
Target Development towards First Production of High-Molar- Activity $^{44g}$Sc and $^{47}$Sc by Mass Separation at CERN-MEDICIS
/ Mamis, Edgars (CERN ; Latvia U.) ; Duchemin, Charlotte (CERN) ; Berlin, Valentina (CERN) ; Bernerd, Cyril (CERN) ; Bovigny, Mathieu (CERN) ; Chevallay, Eric (CERN) ; Crepieux, Bernard (CERN) ; Gadelshin, Vadim Maratovich (Mainz U., Inst. Phys.) ; Heinke, Reinhard (CERN) ; Hernandez, Ronaldo Mendez (CERN ; Havana, ISCTN) et al.
The radionuclides 43Sc, 44g/mSc, and 47Sc can be produced cost-effectively in sufficient yield for medical research and applications by irradiating natTi and natV target materials with protons. Maximizing the production yield of the therapeutic 47Sc in the highest cross section energy range of 24–70 MeV results in the co-production of long-lived, high-γ-ray-energy 46Sc and 48Sc contaminants if one does not use enriched target materials. [...]
2024 - 28 p.
- Published in : Pharmaceuticals 17 (2024) 390
Fulltext: PDF;
|
|
8.
|
10.17181/CERN-THESIS-2019-032
|
9.
|
Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [$^{153}$Sm]Sm-DOTA-TATE
/ Vermeulen, Koen (SCK-CEN, Mol) ; Van de Voorde, Michiel (SCK-CEN, Mol) ; Segers, Charlotte (SCK-CEN, Mol) ; Coolkens, Amelie (SCK-CEN, Mol) ; Pérez, Sunay Rodriguez (SCK-CEN, Mol) ; Daems, Noami (SCK-CEN, Mol) ; Duchemin, Charlotte (Leuven U. ; CERN) ; Crabbé, Melissa (SCK-CEN, Mol) ; Opsomer, Tomas (SCK-CEN, Mol) ; Vargas, Clarita Saldarriaga (SCK-CEN, Mol) et al.
Samarium-153 is a promising theranostic radionuclide, but low molar activities (Am) resulting from its current production route render it unsuitable for targeted radionuclide therapy (TRNT). Recent efforts combining neutron activation of $^{152}$Sm in the SCK CEN BR2 reactor with mass separation at CERN/MEDICIS yielded high-Am $^{153}$Sm. [...]
2022 - 15 p.
- Published in : Pharmaceutics 14 (2022) 2566
Fulltext: PDF;
|
|
10.
|
Efficient Production of High Specific Activity Thulium-167 at Paul Scherrer Institute and CERN-MEDICIS
/ Heinke, Reinhard (CERN ; Leuven U.) ; Chevallay, Eric (CERN) ; Chrysalidis, Katerina (CERN) ; Cocolios, Thomas E (Leuven U.) ; Duchemin, Charlotte (Leuven U. ; CERN) ; Fedosseev, Valentin N (CERN) ; Hurier, Sophie (Leuven U. ; SCK-CEN, Mol) ; Lambert, Laura (CERN) ; Leenders, Benji (Leuven U. ; SCK-CEN, Mol ; Gent U.) ; Marsh, Bruce A (CERN) et al.
Thulium-167 is a promising radionuclide for nuclear medicine applications with potential use for both diagnosis and therapy (“theragnostics”) in disseminated tumor cells and small metastases, due to suitable gamma-line as well as conversion/Auger electron energies. However, adequate delivery methods are yet to be developed and accompanying radiobiological effects to be investigated, demanding the availability of $^{167}$Tm in appropriate activities and quality. [...]
2021
- Published in : Frontiers in Medicine 8 (2021) 712374
Fulltext: PDF;
|
|